Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells

Brian J. Druker; Shu Tamura; Elisabeth Buchdunger; Sayuri Ohno; Gerald M. Segal; Shake Fanning; Jürg Zimmermann; Nicholas B. Lydon

doi:10.1038/nm0596-561

Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells

Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shake Fanning, Jürg Zimmermann, Nicholas B. Lydon

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

3155 Scopus citations

Abstract

The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.

Original language	English (US)
Pages (from-to)	561-566
Number of pages	6
Journal	Nature medicine
Volume	2
Issue number	5
DOIs	https://doi.org/10.1038/nm0596-561
State	Published - 1996

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1038/nm0596-561

Cite this

@article{e19f67ef5a0e48888efb542cbac3d600,

title = "Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells",

abstract = "The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.",

author = "Druker, {Brian J.} and Shu Tamura and Elisabeth Buchdunger and Sayuri Ohno and Segal, {Gerald M.} and Shake Fanning and J{\"u}rg Zimmermann and Lydon, {Nicholas B.}",

year = "1996",

doi = "10.1038/nm0596-561",

language = "English (US)",

volume = "2",

pages = "561--566",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells

AU - Druker, Brian J.

AU - Tamura, Shu

AU - Buchdunger, Elisabeth

AU - Ohno, Sayuri

AU - Segal, Gerald M.

AU - Fanning, Shake

AU - Zimmermann, Jürg

AU - Lydon, Nicholas B.

PY - 1996

Y1 - 1996

N2 - The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.

AB - The bcr-abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease. A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr-Abl fusion protein. Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compound. In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the number of bcr-abl colonies formed but no inhibition of normal colony formation. This compound may be useful in the treatment of bcr-abl-positive leukemias.

UR - http://www.scopus.com/inward/record.url?scp=0029947186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029947186&partnerID=8YFLogxK

U2 - 10.1038/nm0596-561

DO - 10.1038/nm0596-561

M3 - Article

C2 - 8616716

AN - SCOPUS:0029947186

SN - 1078-8956

VL - 2

SP - 561

EP - 566

JO - Nature Medicine

JF - Nature Medicine

IS - 5

ER -

Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this